Halozyme Therapeutics HALO Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Halozyme Therapeutics (HALO) reported comprehensive income (loss), net of tax, attributable to parent of $155.44M in Q1 2026.
- How has Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Halozyme Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 40.2% year-over-year, from $110.85M to $155.44M.